Amneal Pharmaceuticals/$AMRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amneal Pharmaceuticals
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Ticker
$AMRX
Sector
Primary listing
Employees
8,300
Headquarters
Website
AMRX Metrics
BasicAdvanced
$3.1B
921.74
$0.01
1.12
-
Price and volume
Market cap
$3.1B
Beta
1.12
52-week high
$10.34
52-week low
$6.69
Average daily volume
1.7M
Financial strength
Current ratio
1.431
Quick ratio
0.835
Long term debt to equity
-4,807.274
Total debt to equity
-5,525.011
Interest coverage (TTM)
1.53%
Profitability
EBITDA (TTM)
625.178
Gross margin (TTM)
37.43%
Net profit margin (TTM)
0.12%
Operating margin (TTM)
13.31%
Effective tax rate (TTM)
42.62%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
6.85%
Return on equity (TTM)
-201.75%
Valuation
Price to earnings (TTM)
921.744
Price to revenue (TTM)
1.09
Price to book
-28.01
Price to tangible book (TTM)
-2.31
Price to free cash flow (TTM)
11.892
Free cash flow yield (TTM)
8.41%
Free cash flow per share (TTM)
0.841
Growth
Revenue change (TTM)
9.81%
Earnings per share change (TTM)
-101.58%
3-year revenue growth (CAGR)
10.36%
3-year earnings per share growth (CAGR)
-77.02%
What the Analysts think about AMRX
Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.
Bulls say / Bears say
FDA approval of Brekiya® (dihydroergotamine mesylate) autoinjector for acute migraine and cluster headache strengthens Amneal’s specialty portfolio, lifting shares 6% in premarket trading upon the news (Reuters).
Securing a $2.1 billion seven-year Term B loan at SOFR+3.50% and issuing $600 million in 6.875% senior secured notes due 2032 cuts interest expenses, pushes debt maturities out to 2032, and improves liquidity (SEC 8-K).
JPMorgan upgraded Amneal to “Overweight” with a $12 price target, citing a strong Crexont® launch and robust portfolio performance, suggesting shares could gain about 43% and signaling positive analyst sentiment (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AMRX Financial Performance
Revenues and expenses
AMRX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amneal Pharmaceuticals stock?
Amneal Pharmaceuticals (AMRX) has a market cap of $3.1B as of September 14, 2025.
What is the P/E ratio for Amneal Pharmaceuticals stock?
The price to earnings (P/E) ratio for Amneal Pharmaceuticals (AMRX) stock is 921.74 as of September 14, 2025.
Does Amneal Pharmaceuticals stock pay dividends?
No, Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Amneal Pharmaceuticals dividend payment date?
Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amneal Pharmaceuticals?
Amneal Pharmaceuticals (AMRX) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.